Explore Dr. Shady Abohashem’s latest AHA cholesterol study, which reveals that millions of adults have LDL cholesterol levels above recommended targets under the 2026 guidelines and may be missing preventive treatment.
Heart disease remains one of the leading causes of death worldwide, making cholesterol management a top public health priority. A recent study led by Dr. Shady Abohashem, an investigator at Massachusetts General Hospital and Harvard Medical School, has drawn significant attention after examining how Americans measure up against the 2026 American Heart Association (AHA) and American College of Cardiology (ACC) cholesterol guidelines. The findings suggest that millions of people have LDL (“bad”) cholesterol levels above recommended targets and are not receiving appropriate treatment.
What Was the Study About?
Dr. Abohashem and his research team analyzed data from the National Health and Nutrition Examination Survey (NHANES) 2021–2023, representing approximately 178 million U.S. adults. The goal was to evaluate how well the population meets the updated cholesterol recommendations introduced in the 2026 ACC/AHA dyslipidemia guideline.
The researchers focused on low-density lipoprotein cholesterol (LDL-C), commonly referred to as “bad cholesterol,” because elevated LDL levels are a major risk factor for heart attacks, strokes, and other cardiovascular diseases.
Key Findings of the Research
The study found that nearly one in three adults without existing cardiovascular disease had LDL cholesterol levels above the new recommended targets. Even more concerning, about three out of four people in this group were not taking any cholesterol-lowering medication, despite potentially benefiting from treatment.
Among people who had already experienced a heart attack, stroke, or another cardiovascular event, almost four in five still had LDL cholesterol levels higher than the updated guideline recommends. These findings highlight a substantial gap between evidence-based recommendations and real-world care.
Why the New Guidelines Matter
The 2026 ACC/AHA guidelines introduced lower LDL cholesterol goals for individuals at increased cardiovascular risk. They also recommend using the PREVENT-ASCVD risk calculator and encourage broader use of tests such as Lipoprotein(a) and Apolipoprotein B (ApoB) to improve risk assessment.
The updated recommendations reflect growing scientific evidence that lowering LDL cholesterol can significantly reduce the likelihood of future heart attacks and strokes, especially in high-risk individuals.
What This Means for Patients
The study does not mean that everyone should immediately begin taking cholesterol-lowering medication. Instead, it emphasizes the importance of individualized care based on a person’s overall cardiovascular risk, age, family history, and medical conditions.
Experts encourage adults to have regular cholesterol screenings, discuss their risk profile with healthcare providers, and adopt heart-healthy habits such as regular exercise, a balanced diet, maintaining a healthy weight, and avoiding tobacco use. Medication decisions should always be made in consultation with a qualified healthcare professional.
Conclusion
Dr. Shady Abohashem’s latest cholesterol study serves as an important reminder that preventing cardiovascular disease requires both updated medical guidelines and timely patient care. By identifying millions of adults who may not be receiving appropriate cholesterol management, the research highlights an opportunity to reduce preventable heart attacks and strokes. As healthcare providers begin implementing the 2026 cholesterol recommendations, this study could play a key role in shaping future prevention strategies.
